Citations

Clear

4510 citation(s) found for "Scott, C".

Clinical Outcomes of Mitral Regurgitation Severity and Transcatheter Edge‐to‐Edge Repair in Atrial Functional Mitral Regurgitation
Naser, Jwan A. , Massad, Faysal, Borlaug, Barry A. , Simard, Trevor , Siontis, Konstantinos C. , Kennedy, Austin M , Thaden, Jeremy J. , Eleid, Mackram F. , Borlaug, Barry A , Simard, Trevor , Eleid, Mackram F , Naser, Jwan A , Scott, Christopher G. , Michelena, Héctor I. , Pellikka, Patricia A. , Nkomo, Vuyisile T. , Pislaru, Sorin V.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 5, 2025 | Volume: 106 | Issue: 1 | Pages: 494-503

10.1002/ccd.31567 | PMID 40320723 Get It

ABSTRACT Background Incident atrial functional mitral regurgitation (AFMR) is associated with mortality. Transcatheter edge‐to‐edge repair (TEER) has shown effectiveness in improving MR and symptoms in AFMR, but previous studies lacked comparison to conservative management. We aimed to study the association of AFMR severity and mitral TEER with symptoms, heart failure hospitalizations (HFH) and all‐cause mortality in moderate/severe AFMR. Methods Consecutive adults with moderate/severe AFMR managed conservatively or with TEER 2010−2023 were identified retrospectively. To ensure similar technique in evaluation in the two groups, variables were obtained from the closest transthoracic echocardiogram before TEER in the TEER group. In addition to multivariable analysis, the association of TEER (vs. conservative management) with HFH and mortality was assessed using propensity‐score matched analyses; the propensity score was based on age, sex, EuroSCORE II, effective regurgitant orifice area, integrative MR severity, and NYHA class III/IV (vs. I/II). Results Among 230 patients with moderate/severe AFMR [mean age 77; 56% females], 46 were managed with TEER. Severe (vs. moderate) AFMR was independently associated with baseline NYHA class III/IV (multivariable OR 2.18 [95% CI 1.13−4.26]) and HFH [multivariable HR 2.75 (95% CI 1.25−6.03)] but not mortality ( p = 0.26). TEER improved MR to ≤ moderate in 93% but was not associated with lower HFH or death rates versus conservative management on multivariable or matched analysis. However, 1‐year NYHA improved more with TEER versus conservative management in patients with baseline NYHA class III/IV (62% vs. 27%, p = 0.03). Rhythm control was associated with improved survival (HR 0.38 [0.15−0.98]). Conclusions AFMR severity was associated with symptoms and HFH but not mortality. MR severity and NYHA class improved with TEER, but the association of TEER with HF hospitalizations or death remains unproven. Randomized studies are needed to evaluate the potential role of TEER and rhythm control on outcomes in AFMR.
Exploring the effects of glucagon-like peptide-1 receptor agonists on ventricular arrhythmias: a propensity score-matched analysis
Tan, Min Choon , Vignarajah, Aravinthan , Yeo, Yong Hao , Lee, Justin Z. , Russo, Andrea M. , Scott, Luis R. , Sorajja, Dan , Yeo, Yong Hao , Tan, Min C

Mayo Clinic

Europace | May 2, 2025 | Volume: 27 | Issue: 5 | Pages: No page available

10.1093/europace/euaf090 | PMID 40314211 Get It

Insufflation of the gastric remnant from a transduodenal approach facilitates percutaneous gastrostomy tube placement in a post Roux-en-Y patient
Yousif, Paul , Thompson, Scott M. , Jundt, Michael C., Yousif, Paul

Mayo Clinic

American Journal of Interventional Radiology | May 2, 2025 | Volume: 9 | Issue: No issue available | Pages: 4

10.25259/ajir_62_2024 Get It

Percutaneous gastrostomy tube insertion in post Roux-en-Y patients can be challenging due to decompression of the excluded stomach and its discontinuity with the proximal enteric tract. Presented here is a 65-year-old woman status post Roux-en-Y gastric bypass who required gastrostomy tube placement for enteral feeding. The remnant stomach collapsed, and direct percutaneous gastric access was not possible for insufflation. To facilitate insufflation, computed tomography (CT) was used to access the duodenal bulb. This duodenal access was used to insufflate the stomach in a retrograde fashion which created a safe percutaneous window for gastrostomy tube placement into the remnant stomach. The technique described in this study can be a useful tool in patients with difficult to access remnant stomachs. Utilizing either direct or transhepatic access to the duodenum with ultrasound or CT guidance for remnant stomach insufflation can facilitate gastrostomy tube placement in challenging cases.
Using digital platforms to address inequities in neuropsychology training and education: lessons learned from KnowNeuropsychology
Wong, Christina G. , MacDonald, Beatriz , Tan, Alexander , Fox‐Fuller, Joshua T. , McBride, Willie F., Gooding, Amanda, Driskell, Lucas D. , Bene, Victor A. Del , Murriel, Emily C. , Block, Cady, Reyes, Anny , Maietta, Julia E. , Calamia, Matthew , Sperling, Scott A. , Block, Cady K.

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | April 29, 2025 | Volume: 47 | Issue: 9-10 | Pages: 924-938

10.1080/13803395.2025.2497303 | PMID 40296781 Get It

Innovation and inequity in psychedelic research at the Mayo Clinic
Klim, Casimir , VanDreese, Bryan, Meyerhoefer, Terence, Breitinger, Scott , Meyerhoefer, Terence

Mayo Clinic

History of Psychiatry | April 28, 2025 | Volume: 36 | Issue: 1-3 | Pages: 3-15

10.1177/0957154x251318489 | PMID 40293719 Get It

This paper provides an overview of psychedelic research at the Mayo Clinic in the 1950s and 1960s, focusing on methods, objectives, findings, and ethical practices. We highlight instances where researchers prioritized scientific progress over the autonomy, safety, and equitable treatment of research subjects, and discuss this history in the context of ongoing challenges with informed consent and equity in contemporary psychedelic research.
101. Factors Influencing Reduced Postoperative Hospital Stay in DIEP Flap Breast Reconstruction
Mazarei, Michael, Solomon, Santana, Kenner, Hayley, Lombana, Nicholas F. , Saint‐Cyr, Michel, Solomon, Santana, Jukic, Alma , Oberoi, Michelle K.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 25, 2025 | Volume: 13 | Issue: S1 | Pages: 70-70

10.1097/01.gox.0001112352.19509.fe Get It

Abstract CT269: First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited
Choudhry, Modassir, Folsom, Timothy D., Rathmann, Blaine, DeFeo, Anthony P. , Kim, Ji Hyun , Sumstad, Darin , Klebanoff, Christopher A. , Ladner, Katherine J., Sarkari, Akshat , McIvor, R. Scott , Rao, Madhuri , Ankeny, Jacob S. , Khalifa, Mahmoud A. , Chauhan, Anil , Dixit, Ajay , Weber, Daniel , Byrne‐Steele, Miranda, Henley, Tom , McKenna, David H. , Johnson, M. J. , Webber, Beau R. , Webber, Beau R , Lou, Emil , Starr, Timothy K. , Bell, Jason B , Slipek, Nicholas J. , Jin, Zhao-Hui , Murray, Thomas A. , Miller, Jeffrey S. , Jensen, Eric Hans , Spilseth, Benjamin , Provenzano, Paolo P. , Pan, Wenjing , Moriarity, Branden S.

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT269-CT269

10.1158/1538-7445.am2025-ct269 Get It

Abstract Background: Given the dramatic rise in incidence of colorectal cancer in young adults, there remain limited treatment options effective in metastatic disease. Although T cell-based therapies have been successful in treating highly antigenic cancers, like melanoma and lung, they have not yet been shown to induce consistent and durable tumor regression in common epithelial malignancies, including metastatic colorectal cancer (mCRC). CISH (Cytokine inducible SH2 containing protein) is a novel intracellular checkpoint target demonstrating PD-L1 ligand independent mechanisms of enhanced anti-cancer activity. Given that CISH is not currently tractable via antibody or small molecule drug modalities, we employed CRISPR for precise inhibition of CISH in tumor infiltrating lymphocytes (TILs). Here, we provide the first clinical report of safety and anti-tumor activity of CISH edited TILs in 12 patients with metastatic gastrointestinal cancers (NCT04426669), including a clinical complete response (CR) in a young-adult patient with immunotherapy-refractory mCRC. Methods: Tumors were surgically resected for TIL harvest, followed by a rapid expansion protocol and CRISPR/Cas9 knockout (KO) CISH. CISH KO, neoantigen-reactive TILs were expanded, then infused following non-myeloablative lymphocyte depleting (LD) chemotherapy (cyclophosphamide & fludarabine) followed by high-dose IL-2. To establish mechanistic attribution of the CR, we used iR-RepSeq+ for serial analysis of the TCR immune repertoire. Results: Our CRISPR engineering led to KO of CISH in T cells with high-efficiency (>90%) without detectable off-target editing. We safely dosed patients at all five dose levels (range: 1.91e8 to 9.93e10 cells). No dose-limiting toxicities attributable to the CISH-KO TIL product were observed. Adverse events were consistent with established risks of LD chemotherapy, IL-2, or disease progression. A durable ongoing complete response (>21 months) was achieved in a patient with microsatellite instability-high (MSI-H) mCRC refractory to anti-PD1/CTLA-4 combination therapy. Conclusions: We provide the first clinical report of CISH checkpoint targeting via genetically modified T cell therapy, with complete response in a patient with mCRC. Persistence and expansion of unique TCR clonotypes detected in neoantigen responsive TIL was temporally consistent with spikes in CISH edited alleles detected by NGS assay; in the patient with CR, four of the clonotypes exhibiting prolonged persistence greater than one-year post-infusion exhibited significantly reduced or undetectable expression of CISH compared to the total infused TIL population. Given these findings, further investigation of CISH checkpoint inhibition, via gene and cell therapy, and next-generation small molecule drugging modalities, is underway. Citation Format: Emil Lou, Modassir S. Choudhry, Timothy K. Starr, Timothy Folsom, Jason Bell, Blaine Rathmann, Anthony P. DeFeo, Ji Hyun Kim, Nicholas Slipek, Zhaohui Jin, Darin Sumstad, Christopher A. Klebanoff, Katherine Ladner, Akshat Sarkari, R Scott McIvor, Thomas A. Murray, Jeffrey Miller, Madhuri Rao, Eric Jensen, Jacob Ankeny, Mahmoud A. Khalifa, Anil Chauhan, Benjamin Spilseth, Ajay Dixit, Paolo P. Provenzano, Wenjing Pan, Daniel Weber, Miranda Byrne-Steele, Tom Henley, David H. McKenna, Matthew J. Johnson, Beau R. Webber, Branden S. Moriarity. First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT269.
Deep Learning Model for Histologic Diagnosis of Dysplastic Barrett's Esophagus: Multisite Cohort External Validation
Codipilly, Don C. , Faghani, Shahriar , Vogelsang, David C. , Erickson, Bradley J. , Garg, Nikita , Lewis, Jason , Leggett, Cadman L. , Konda, Vani J. , Diffalha, Sameer Al , Peter, Shajan, Brinkerhoff, Brian , Wong, Mary , Otaki, Fouad , Katzka, David A. , Wani, Sachin , Shaheen, Nicholas J. , Iyer, Prasad G. , Codipilly, Don Chamil , Vogelsang, David, Erickson, Bradley J , Hagen, Catherine E , Leggett, Cadman L , Konda, Vani , Wong, Mary , Otaki, Fouad , Katzka, D A , Faghani, Shahriar , Hagen, Catherine E. , Patil, Pallavi

Mayo Clinic

American Journal of Gastroenterology | April 23, 2025 | Volume: 121 | Issue: 4 | Pages: 863-870

10.14309/ajg.0000000000003495 | PMID 40267276 Get It

INTRODUCTION: The risk of progression to esophageal adenocarcinoma in Barrett's esophagus (BE) increases with advancing degrees of dysplasia. There is a critical need to improve the diagnosis of BE dysplasia, given substantial interobserver variability and overcalls of dysplasia during manual community pathologist reads. We aimed to externally validate a previously cross-validated BE dysplasia diagnosis deep learning model (BEDDLM) that predicts dysplasia grade on whole slide images (WSIs). METHODS: We digitized nondysplastic BE (NDBE), low-grade (LGD), and high-grade dysplasia (HGD) histology slides from 3 external academic centers. A consensus read by 2 expert study pathologists was used as the criterion standard. Slide stain characteristics were normalized using cycle-generative adversarial networks. WSIs were assessed by BEDDLM using an ensemble approach, combining a “You Only Look Once” model followed by a ResNet101 classifier model. RESULTS: We included 489 WSIs. Consensus histopathology revealed 232 NDBE, 117 LGD, and 140 HGD WSIs. The mean age (SD) was 66.9 (11.4) years; 413 (84.7%) were men. Using the BEDDLM ensemble model, sensitivity and specificity for NDBE were 73.3% (95% confidence interval [CI]: 67.09%–78.85%) and 93.4% (95% CI: 89.62%–96.10%); for LGD, 84.6% (95% CI: 76.78%–90.62%) and 80.6% (95% CI: 76.26%–84.54%); and for HGD, 80.7% (95% CI: 73.19%–86.89%) and 94.8% (95% CI: 91.97%–96.91%), respectively. The F1 score was 0.81, 0 0.69, and 0.83 for NDBE, LGD, and HGD, respectively. DISCUSSION: Our externally validated deep learning model demonstrates substantial accuracy for the diagnosis of BE dysplasia grade on WSIs.
Single cell resolution of an epigenetic signature of persister tumor cells
Dumbravă, Mihai , Sandoval, Letícia , Mazzone, Amelia , Aalam, Syed Mohammed Musheer , Ritting, Megan L. , Hou, Xiaonan , Xie, Yiwen , Harrington, Shariska P. , Kaufmann, Scott H. , Weroha, S. John , Kaufmann, Scott H , Dumbrava, Mihai , Mazzone, Amelia , Musheer Aalam, Syed Mohammed , Ismail, Wazim Mohammed , Kannan, Nagarajan , Gaspar‐Maia, Alexandre

Mayo Clinic

No container title available | April 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.16.649175 Get It

Abstract Cancer can recur when a subset of tumor cells, denoted here as persister cells, are able to survive therapy and re-enter the cell cycle. The precise mechanisms that confer the persister state and whether it is characteristic of a subgroup of cells or arises from multiple cellular lineages remain poorly understood. We hypothesize that an epigenetic signature underlies the drug-tolerant persister state, characterized by transcriptional and chromatin accessibility changes that promote survival of residual cancer following chemotherapy. To identify clinically relevant features of persister cells in untreated tumors and residual disease, we performed single-cell multiomic profiling (snRNA+snATAC) on a cohort of non-malignant fallopian tube, treatment-naïve, and neoadjuvant chemotherapy (NACT)-treated high-grade serous ovarian cancer (HGSOC) samples. We identified differences in gene expression and open chromatin between naïve and residual patient tumors following chemotherapy. Although only a small proportion of the differentially expressed genes enriched in residual HGSOC overlapped with established gene sets for chemo-response and patient prognosis, the epigenomic analysis revealed activity of several DNA-binding factors that are both enriched upon chemotherapy and also high in resistant tumors prior to treatment. From this analysis, we identified an epigenetic signature that precedes expression and defines the persister state. This epigenetic signature also correlated with chemotherapy sensitivity and resistance using patient-derived xenograft models of HGSOC. Gene regulatory networks driven by the persister signature are involved in the activation of oncogenic pathways, including changes to the cell cycle promoting quiescence and stress response. Further study of the persister cells identified by this epigenetic signature may increase understanding of the mechanisms underlying persister cell survival and reveal new vulnerabilities that could be exploited to delay or prevent cancer recurrence.